What Is a GLP-1?

1. What Does GLP-1 Mean?

GLP-1 stands for glucagon-like peptide-1. NCBI MeSH describes it as a peptide derived from proglucagon and mainly produced by intestinal L cells. It affects glucose-dependent insulin release, glucagon release, gastric emptying, blood glucose, and food intake.

In everyday language, “GLP-1” is often used as shorthand for GLP-1 receptor agonist medications such as semaglutide or the dual GIP/GLP-1 receptor agonist tirzepatide. While common, this shorthand blurs the difference between the naturally occurring hormone and a prescribed drug product.

2. What Are GLP-1 Receptor Agonists?

GLP-1 receptor agonists are a medication class used for type 2 diabetes and, increasingly, obesity. Their mechanisms include stimulating insulin secretion after an oral glucose load, delaying gastric emptying, and reducing glucagon production when blood sugar is high.

While these mechanisms explain why the category appears in discussions about metabolic health and diabetes, each specific product has its own label, dosage, warnings, and prescribing context.

3. Why Does GLP-1 Get So Much Attention?

KFF reported in May 2024 that about one in eight U.S. adults had taken a GLP-1 agonist at some point, including 6% who were actively taking one. In that poll, 62% of people who had taken GLP-1 drugs said they used them at least partly for a chronic condition such as diabetes or heart disease.

4. What Are They Approved For, and What Are the Main Risks?

Each product carries only the indications its own trials support, which is why the same molecule is sold under two names.

The size of the effect is well measured. In STEP 1, semaglutide 2.4 mg produced 14.9% mean weight loss over 68 weeks against 2.4% on placebo. In SURMOUNT-1, tirzepatide 15 mg produced 20.9% over 72 weeks against 3.1%. In SELECT, semaglutide cut major cardiovascular events from 8.0% to 6.5% over about 40 months in people with cardiovascular disease and obesity. Those are trial averages in the populations studied, not predictions for an individual, and weight tends to return after stopping; the weight-regain page covers that evidence.

The main risks are the same across the products above and sit at the top of each of those labels. (Two older, less potent exenatide and lixisenatide products, Byetta and the discontinued Adlyxin, carry no boxed warning.) A boxed warning on thyroid C-cell tumors, seen in rodents, with a contraindication for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Warnings on pancreatitis, gallbladder disease, severe gastrointestinal reactions, acute kidney injury from dehydration, and hypoglycemia when combined with insulin or a sulfonylurea. Nausea, vomiting, diarrhea, and constipation are the common side effects, mostly during dose escalation. The drugs are not for use in pregnancy, and the labels ask for a washout of about two months before a planned pregnancy for semaglutide.

5. Tracking a GLP-1

Because these are weekly or daily doses on a stepped ladder, the useful record is simple: product, date, milligrams, injection site for an injection, and any side effect. Half-life is why the record matters: semaglutide’s is about a week, so a dose is still present for around five weeks after the last injection, and a missed or late dose shows up as a gap in that curve. How GLP-1 tracking works covers what to log, and the half-life tracking guide covers the math.

6. What Is a GLP-1 FAQ

• What does GLP-1 stand for?

  GLP-1 stands for glucagon-like peptide-1, a peptide hormone derived from proglucagon and produced mainly by intestinal L cells.

• Are GLP-1 medications the same as natural GLP-1?

  No. Natural GLP-1 is a hormone. GLP-1 receptor agonist medications are drug products designed to activate related receptor pathways and differ in structure, duration, labeling, and approved uses.

• Can a GLP-1 tracker choose a dose?

  No. A GLP-1 tracker records user-entered logs, reminders, inventory, and notes. It cannot decide doses, timing, medical suitability, or product authenticity.

7. Sources